Pharmafile Logo

AI with intent: How Inizio is redefining pharma through precision and partnership

October 29, 2025 | Intelligent Commercialization 

At Fierce Pharma Week, Inizio revealed how the fusion of human expertise and purposeful AI is reshaping pharma communications and driving real-world impact—discover how this human-centered innovation is defining the future of Intelligent Commercialization™.

- PMLiVE

Empowering human insight at Fierce Pharma Week 

This year’s Fierce Pharma Week brought together the leading voices shaping the future of pharmaceutical communications, strategy, and innovation. At Inizio, we had a front-row seat through the contributions of experts, who showcased how we’re combining human expertise with AI to deliver precision, credibility, and measurable impact. 

Across every discussion our experts took part in, one theme stood out: AI delivers its greatest value when guided by intent. From elevating scientific storytelling to advancing field medical enablement and enabling data-driven decision-making, our teams demonstrated how purposeful integration of AI is transforming how pharma connects, learns, and leads. 

Here’s how our experts brought that vision to life at Fierce Pharma Week  through connected insight, practical innovation, and partnership that drives real-world change. 

Engineering credibility in an AI-powered world 

In the session “From earned to engineered,” Inizio Evoke’s Will ReeseTheresa Dolge, and Kelly Cusumano urged pharma communicators to rethink visibility in an AI-shaped world. 

They discussed the rise of “thin” versus “thick” content, concise, discoverable insights that feed AI models versus deeply sourced narratives that build authority. The strongest brands balance both, ensuring that what AI learns is accurate, credible, and humanly resonant. 

As Will noted, “AI rewards content that’s structured, traceable, and solution-oriented.” The key is designing material that both humans and machines can trust, because what’s visible shapes what’s believed. 

Explore the full talk delivered by Inizio Evoke here. 

Building real capability with real impact 

AI delivers the most value when guided by experts who use it with purpose. 

Inizio Medical’s Kelly Malloy, SVP of Customer Engagement for AI and Augmented Intelligence, brought this to life during her talk, “The business case for next-gen field medical enablement,” alongside a panel of industry leaders: 

  • Tiffanie Stewart, PhD, Senior Director, MSLs, Inizio Engage 
  • Donnie Wooten, Jr., PharmD, Senior Director, Global Medical Capabilities – Oncology, AstraZeneca 
  • Michael Kahn, formerly Senior Director, Medical Affairs Operations Leader, Spark Therapeutics 

Using tools like MSL Interact, teams can rehearse realistic HCP conversations in a safe, simulated environment. It’s a powerful example of using AI to enhance human skills like empathy, curiosity, and dialogue, rather than aiming to replace them. The panel highlighted the value of adaptive, continuous learning along with a “Four Ps” model: prepare, practice, perform, pivot. 

“Generative AI is an accelerant, not a shortcut,” Kelly reminded the audience. “When used deliberately, it bridges science and storytelling- helping field teams communicate more clearly and confidently in the moments that matter most.” 

Watch the full talk delivered by Inizio Medical here. 

Transforming medical affairs with data and AI 

Inizio Advisory’s session, “Precision Medical Affairs in action,” led by Lori Klein, Partner, Medical Affairs Practice Lead, brought together expert insights from: 

  • Nikheel Kolatkar, VP, US Medical, Genentech 
  • Loucif Ouyahia, Global Head of Digital Healthcare, Jazz Pharmaceuticals 

They described how precision Medical Affairs moves from reactive to predictive by using AI-driven analytics to uncover care gaps, localize insights, and personalize scientific engagement, connecting data across functions to create continuous feedback loops, and equip teams to partner confidently with AI. 

As Lori summarized, “When you integrate human and machine intelligence, you don’t just find new insights – you create new impact.” 

Watch Inizio Advisory’s Fierce Pharma Week session here.  

Precision launch: aligning data, strategy, and purpose 

In their second session, “Precision launch: Integrating data and AI to power commercial and medical strategy,” Inizio Advisory’s Jo-Ann Saitta, Partner, Global Data Strategy, and Lori Klein, spotlighted the value of data unity and strategic alignment.  

Through centralized, compliant products like ClarityNav, part of the Navigator AI™ pharma teams can align next-best actions, understand the voice of the customer, and orchestrate personalized engagements. When medical and commercial teams operate from a single, trusted source of truth, every insight becomes actionable, and every action measurable. 

This is what modern launch excellence looks like: predictive, connected, and powered by purpose. 

Watch Inizio Advisory’s second Fierce Pharma Week session here. 

Innovation rooted in the human equation 

Every session echoed one essential truth: AI is only as valuable as the people guiding it. Whether in content, training, or analytics, Inizio’s approach to innovation is grounded in the belief that technology should elevate human creativity rather than eclipse it. 

We’re building systems that help decision-makers within healthcare and pharma: 

  • See more clearly 
  • Decide more precisely 
  • Act with greater purpose 

Because empathy, curiosity, and expertise, not algorithms, sustain trust in healthcare. 

From insight to impact with Intelligent Commercialization™ 

Fierce Pharma Week reinforced our mission: to lead the future of Intelligent Commercialization™ – where human insight, data, and AI converge to deliver clarity, speed and measurable impact. 

  • Through strategic intelligenceNavigator AI™ enables faster, smarter portfolio and investment decisions, sharpens strategy, strengthens field execution, and accelerates launches.   
  • Through medical intelligenceiON.AI™ converts scientific evidence into actionable insights that enhance the influence and effectiveness of Medical Affairs execution.   
  • Through commercial intelligenceCognitev™ translates primary generated behavioral data into activation – fueling omnichannel engagement, optimizing field force strategy, and aligning tactics across the lifecycle. 

Together, we help the industry move beyond insight to action through accelerating launches, sharpening strategies, and driving real-world impact across the full lifecycle of commercialization. 

Ready to unlock the power of Intelligent Commercialization™ across your organization? 

Let’s talk about how using AI with intent can elevate your strategy, accelerate impact, and drive smarter engagement across the product lifecycle. Connect with our experts here. 

This content was provided by Inizio

Company Details

 Latest Content from  Inizio 

Event: EULAR Annual European Congress of Rheumatology 2016

We are delighted to be attending the EULAR Annual European Congress of Rheumatology in June. Representing Research Partnership is Business Development Manager, Fara Mboge. He will be on hand to...

Forever Angels achievements and development plan for 2016

Research Partnership is proud to support Forever Angels in their mission of caring for and improving the lives of orphans and abandoned infants in Tanzania

The Opportunity for Women’s Health in Emerging Markets

Published in eyeforpharma April 2016 by Rachel Howard

Video: Storytelling in healthcare market research

Within the pharmaceutical industry, there is an increasing need for market research teams to share the insights with their key internal stakeholders, from marketing and brand managers to sales reps...

Promotions and new appointments across our global offices

Research Partnership is delighted to announce promotions and new starters in the UK and further appointments in the US and Singapore offices

Free Thinking: Are biosimilars the answer to the rising cost of RA treatment?

In a past Free Thinking paper, we looked at the opportunity and challenges for biosimilar mAbs entering the rheumatoid arthritis market. A few years later and according to our Therapy...

Webcast: Understanding the Chronic Disease Patient Journey in Emerging Markets

In emerging markets where primary care systems do not exist, the patient is the only constant in the journey

PEGASUS JOINS ASHFIELD HEALTHCARE COMMUNICATIONS

Pegasus, one of the most successful integrated healthcare communications consultancies in the UK, has today announced it has been acquired by UDG Healthcare plc, a FTSE 250 listed international provider...

Living with Crohn’s Report

Are you looking for a deeper understanding of the emotional needs, behaviours and treatment programmes of patients living with Crohn’s Disease?

Infographic: Research Partnership

Our latest infographic offers an overview of some key facts and figures about the company, its services and capabilities.